|
Rockland Immunochemicals and Emory U sign master reagent pact
March 2011
SHARING OPTIONS:
GILBERTSVILLE, Pa.—Rockland Immunochemicals Inc. and Emory University last month announced a collaboration to
develop novel antibodies and antibody-based tools for cancer, cell signaling and chromatin research. The partners will develop new antibody-based reagents
capable of identifying targets for use on platform technologies currently used in research and clinical laboratories. Rockland supports the biopharma and
diagnostic industries with antibodies and antibody-based tools for basic research, assay development and preclinical studies. The company develops new
technologies for the production of antibodies for western blotting, immunohistochemistry (IHC), immunofluorescence microscopy, ELISA and FLOW cytometry.
"We have used the expertise at Rockland for many years to develop terrific antibody reagents for our basic science projects to understand how the immune system functions. This new collaboration/partnership will allow novel reagents to be developed for both basic science research and ultimately translational applications," says Dr. Jeremy M. Boss, professor and chair of microbiology and immunology at Emory. Back |
Home |
FAQs |
Search |
Submit News Release |
Site Map |
About Us |
Advertising |
Resources |
Contact Us |
Terms & Conditions |
Privacy Policy
|